Loading...
XSHG
603718
Market cap268mUSD
Jul 09, Last price  
2.79CNY
1D
-0.71%
1Q
-38.55%
Jan 2017
-84.34%
IPO
-40.51%
Name

Shanghai Hile Bio-Technology Co Ltd

Chart & Performance

D1W1MN
XSHG:603718 chart
P/E
P/S
9.68
EPS
Div Yield, %
2.81%
Shrs. gr., 5y
-5.79%
Rev. gr., 5y
-6.23%
Revenues
188m
-30.69%
260,127,200310,842,900318,792,700285,272,025316,577,603343,338,733303,650,205254,565,186277,992,965259,128,540347,289,178299,991,674240,722,981271,039,817187,870,337
Net income
-311m
L
107,273,400112,545,800118,789,500101,221,39195,402,61985,536,351113,739,53821,298,22812,151,2318,926,61453,856,684121,607,85162,870,203171,180,300-311,436,622
CFO
59m
+26.60%
149,608,100122,475,830147,626,205110,218,481201,687,364108,388,16734,920,78318,917,48259,251,287167,682,48943,632,976292,905,014-2,938,20946,473,09058,832,698
Dividend
Jul 15, 20250.0784 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry reagents, latex enhanced immune turbidimetry reagents, enzyme-linked immunosorbent products, and related diagnostic kits, including matrix metalloproteinase 3, IV collagen, adiponectin, creatine kinase isoenzyme, hepatic bile acid, cardiac troponin I, heparin binding protein, hemoglobin A1C, lipoprotein phospholipase A2, heart fatty acid binding protein, ferritin, sialoglycoside antigen, and procalcitonin kits. The Oral Tissue Repair and Regeneration Materials segment provides oral bone repair materials, implant systems, natural bone repair materials, oral restorative films, collagen-based bone repair matrices, and soft tissue repair matrices, primarily for dental implantation and maxillofacial bone defect repair. The company was founded in 1981 and is headquartered in Shanghai, China.
IPO date
May 15, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT